期刊
SUPPORTIVE CARE IN CANCER
卷 29, 期 7, 页码 4033-4043出版社
SPRINGER
DOI: 10.1007/s00520-020-05928-6
关键词
Chemotherapy-induced peripheral neuropathy; Cancer; Adverse drug reaction; Oncologists; Professional practice
Chemotherapy-induced peripheral neuropathy (CIPN) is challenging for oncologists, with high incidence and lack of effective preventive/management strategies. A survey of French oncologists revealed awareness of CIPN risks, but underestimation of incidence and poor adherence to ASCO recommendations for management. Prevention, diagnosis, and management of CIPN remain problematic in clinical practice in France.
Purpose Chemotherapy-induced peripheral neuropathy (CIPN) is challenging for oncologists. Many publications mention the high incidence of CIPN and the lack of effective preventive/management strategies and robust diagnostic tools. This cross-sectional study was aimed at assessing the practice of French oncologists for CIPN prevention, diagnosis and management. Methods This web-based survey was sent to French oncologists by the regional cancer networks. Incidence and impact of CIPN were assessed using visual analogue scales (VAS) and diagnostic strategies were recorded. Also recorded were the drugs used to prevent or manage CIPN and their perceived efficacy and safety (VAS). Results Among the 210 oncologists included, the perceived incidence of CIPN was about 36.2 +/- 22.1% of patients. About 99.5% of oncologists declared that they assess CIPN during medical follow-up. The use of drugs to prevent CIPN was reported by 9.6% of oncologists (group B vitamins (35.0%) and calcium and magnesium infusion (25.0%)). In the case of CIPN, the therapeutic adjustment of neurotoxic anticancer drugs is performed by 99.0% of oncologists (chemotherapy change (49.8%), dose reduction (30.9%) or interruption (19.3%)). The pharmacological management of CIPN was declared by 72.9% of oncologists. The main drugs used are pregabalin (75.8%), amitriptyline (32.7%) and gabapentin (25.5%). Duloxetine (ASCO recommendation) is used by only 11.8% of oncologists. Conclusion Oncologists were clearly aware of CIPN risks, but its incidence tended to be underestimated and the ASCO recommendations for the management of CIPN were not followed. The prevention, diagnosis and management of CIPN remain problematic in clinical practice in France.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据